Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
Biome Australia Surges with 41% YoY Revenue Growth in Q2 FY26
Biome Australia (ASX: BIO) has reported a robust Q2 FY26, with revenue surging 40.9% year-on-year to $6.48 million, significantly exceeding expectations and reinforcing its trajectory towards its 'Vis
Latest Stories
AdAlta inks major CAR-T deal for global development outside China
AdAlta (ASX:1AD) has secured exclusive rights to co-develop Shanghai Cell Therapy Group's BZDS1901 CAR-T therapy outside Greater China, a significant move validating its 'East-to-West' strategy and po
Memphasys Secures CE Mark for Felix System, Unlocking European Market
Memphasys (ASX: MEM) has secured CE Mark approval for its Felix System, unlocking immediate commercial opportunities in Europe and activating binding multi-year contracts in Europe and MENA.
Korean partner backs Invion’s INV043 ahead of Australia first-in-human trial
Invion (ASX: IVX) partners with Hanlim on a $2m non-clinical program to advance INV043 for oesophageal cancer toward first-in-human trials, backed by KDDF grant.
Neurizon Therapeutics Secures Over $44M in Funding to Advance HEALEY ALS Trial
Neurizon Therapeutics (ASX: NUZ) has successfully raised over $44 million AUD through a multi-pronged capital raise, securing funding to advance its lead drug candidate NUZ-001 through the **H
TrivarX Reports Strong US Veteran Trial Results Supporting Objective Depression Screening
TrivarX (ASX: TRI) has delivered positive results from a US-based clinical trial that demonstrate clinically meaningful, objective detection of current major depressive episodes in veterans using the company’s single-lead electrocardiogram technology.
Island Pharmaceuticals and Texas Biomed to Conduct Non-Human Primate Studies Using Antiviral Drug Galidesivir
Island Pharmaceuticals (ASX: ILA) has secured a master service agreement with Texas Biomedical Research Institute to support the development of lead antiviral molecule galidesivir.
Emyria Establishes First Victorian Empax Clinic for Psychedelic-Assisted Treatments
Perth-based mental health care specialist Emyria (ASX: EMD) has secured its first Empax clinic in Victoria for the psychedelic-assisted treatment of post-traumatic stress disorder (PTSD) and treatment-resistant depression.
Biome Australia Launches First Human Clinical Trial on Proprietary BMB18 Strain
Biome Australia (ASX: BIO) has submitted ethics approval and registered its first human clinical trial on proprietary probiotic strain Lactobacillus plantarum BMB18 with the Australia New Zealand Clinical Trials Registry.
Algorae Pharmaceuticals Identifies 90 New Drug-Combination Candidates from AlgoraeOS V2 Analysis
Algorae Pharmaceuticals (ASX: 1AI) has identified 90 high-quality drug-combination candidates following a preliminary review of newly delivered in silico synergy predictions generated by its upgraded AlgoraeOS v2 platform.
Artrya Secures Second US Commercial Order for Salix SaaS Platform to Manage Coronary Artery Disease
Artrya (ASX: AYA) has signed a commercial agreement with US-based Northeast Georgia Health System for the use of its Salix AI cloud platform for point-of-care assessment and management of coronary artery disease.
Algorae Pharmaceuticals Achieves Independent Validation of AlgoraeOS and Launches Enhanced v2 Platform
Algorae Pharmaceuticals (ASX: 1AI) has reported independent preclinical validation of its AlgoraeOS v1 drug-combination prediction platform following a major study at the Victorian Centre for Functional Genomics at the Peter MacCallum Cancer Centre.